MedTrace Logo

Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration

NCT00460408 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 501

Last updated 2012-12-11

Study results available
· View outcomes & findings →

Summary

The study will provide additional safety data for specific safety events in persons receiving intravitreal injections. The Committee for Medicinal Products for Human Use (CHMP) is interested in obtaining additional safety information when Macugen is used in real world settings by practitioners in Europe treating patients with neovascular (wet) age-related macular degeneration (AMD). The study will provide information about physician practice patterns and characteristics of patients treated with Macugen.

Conditions

  • Macular Degeneration

Interventions

DRUG

Macugen

Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2012-02-29
Completion
2012-02-29

Countries

  • Belgium
  • Cyprus
  • Czechia
  • Denmark
  • France
  • Germany
  • Greece
  • Ireland
  • Italy
  • Poland
  • Slovakia
  • Spain
  • Sweden

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00460408 on ClinicalTrials.gov